The COVID-19 pandemic was a harsh lesson for the entire world. Africa, home to 20% of the global population, produced just 0.1% of the world’s vaccines. When the crisis hit, the continent found itself at the back of the queue for life‑saving doses.
That will not happen again. Gavi, the Vaccine Alliance, has made a historic decision. In July 2026, the Gavi Board approved a $189 million package of measures to accelerate African vaccine manufacturing. The program is called AVMA+ – an extension of the African Vaccine Manufacturing Accelerator (AVMA), launched in 2024.
For Kenya, this is not just news from the global health world. It’s a direct signal: the country could become one of the main beneficiaries of these investments. Kenya already has the capacity, the strategy, and the political will. All that remains is to seize the moment.
While the world discusses new opportunities for African pharmaceuticals, thousands of Kenyans are following developments through mobile apps – including 888bet download – staying informed about how these changes will affect their lives and health.
What Is AVMA+ and Why Does It Matter
AVMA is not just a programme. It is a response to a systemic problem.
Launched in 2024 in close collaboration with the African Union and Africa CDC, AVMA offers manufacturers up to $1 billion in incentives for reaching key regulatory and production milestones. Over 18 months, the programme has already helped secure 13 technology transfer agreements, leading to the construction of commercial manufacturing facilities in six African countries.
AVMA+ is the next step. It addresses two main challenges:
- Regulatory and market barriers. Many African manufacturers are ready to produce vaccines but face bureaucratic hurdles. AVMA+ will help overcome them.
- Guaranteed demand. Gavi will directly purchase up to 70 million doses of African vaccines through competitive tenders. This gives manufacturers confidence: they are not investing in production blindly.
Gavi CEO Dr. Sania Nishtar said: “As our manufacturing partners continue their journey towards pre‑qualification and full commercialisation, we believe the new AVMA+ investments will accelerate the timeline when demand for vaccines in Africa will be met by local production.”
And this could happen as early as 2027 – the first vaccines produced in Africa with AVMA support could reach the market.
Kenya Is Already in the Game
Kenya is not just a spectator. The country is actively preparing to become a regional hub for vaccine and pharmaceutical manufacturing.
Here’s what has already been done:
| Investment / Project | Amount | Capacity / Status |
| Vaccine fill‑and‑finish plant (Kenya BioVax Institute) | $60.8 million | 72 million doses per year |
| Full‑cycle production plant (Konza Technopolis) | $248 million | Under construction |
| Participation in mRNA technology transfer programme (WHO/Médecins Patent Pool) | – | Production of vaccines against COVID‑19, malaria, tuberculosis |
Kenya is already the third largest exporter of pharmaceutical products in Africa and the largest supplier within COMESA, accounting for nearly half of that regional market. Over 37 licensed manufacturers produce 694 drug formulations – from paracetamol to other essential medicines. Pharmaceutical exports grew from 12.2 billion shillings in 2022 to 19.9 billion in 2024 – a 63% increase.
Health Cabinet Secretary Aden Duale has repeatedly emphasised: “Health security cannot be outsourced. Countries that do not produce the medical products they need remain vulnerable to external shocks.”
In February 2026, Kenya joined the WHO and MPP mRNA technology transfer programme. This allows the Kenya BioVax Institute to scale up production of vaccines against COVID‑19, malaria, tuberculosis, and other diseases.
What Gavi Offers Kenya
The AVMA+ programme opens specific opportunities for Kenya.
Here are the key areas of benefit for the country:
- Access to guaranteed procurement. Gavi will purchase up to 70 million doses of African vaccines. Kenyan manufacturers can participate in tenders and secure long‑term contracts.
- Overcoming regulatory barriers. AVMA+ will help manufacturers faster achieve WHO pre‑qualification and gain access to international markets.
- Attracting investment. Confidence in demand attracts private capital. Gavi has already mobilised $3 billion in additional financing since AVMA was launched.
- Strengthening Kenya’s position as a regional hub. The country already leads in East Africa. New investments will reinforce that leadership.
- Reducing import dependence. Kenya still imports 70–80% of the pharmaceuticals it consumes. Developing domestic production is a matter of national security.
In 2026, Kenya also joined the WHO‑MPP mRNA Technology Transfer programme, enabling Kenya BioVax Institute to scale up production of next‑generation vaccines.
While the government and international partners shape strategy, many Kenyans are following developments through digital platforms – such as 888bet apk – to understand how these changes will affect their everyday lives.
Five Steps Kenya Has Already Taken
Here are concrete actions by the Kenyan government that are preparing the country to seize AVMA+ opportunities:
- Launch of the local manufacturing strategy for 2026–2030. In June 2026, Kenya officially presented a five‑year plan to develop the production of medicines, vaccines, and medical devices.
- Plant construction. A vaccine fill‑and‑finish plant with a capacity of 72 million doses per year is already operational. A full‑cycle plant at Konza Technopolis is under construction.
- Regulatory reform. Kenya is working towards achieving WHO Global Benchmarking Tool Maturity Level 3 – which will allow faster certification of manufacturers and simplify exports.
- Collaboration with India. In July 2026, Kenya and India announced a health investment summit to accelerate local vaccine and pharmaceutical production.
- Joining the mRNA programme. Participation in the global technology transfer network provides access to know‑how and patents.
President William Ruto, who chairs the African Union’s local manufacturing initiative, is actively advancing this agenda on the continent.
What’s Next: A Forecast for Kenya
The AVMA+ programme is just beginning. The first payments to manufacturers are expected in the second half of 2026. And the first vaccines produced in Africa with AVMA support could arrive as early as 2027.
For Kenya, this means a window of opportunity:
- Kenyan manufacturers can apply to participate in the programme
- The country can attract new investors thanks to guaranteed demand
- Strengthening the regulatory system will make Kenya more attractive to pharmaceutical companies
- Reducing import dependence will increase the resilience of the healthcare system
However, challenges remain. Kenyan manufacturers currently use less than half of their capacity. The new strategy aims to increase utilisation to 70% by 2030. There is also work to be done on meeting international GMP quality standards and implementing multi‑year procurement contracts.
WHO Representative in Kenya, Dr. Nima Roushabila Kiambo, emphasised: “As Kenya expands local production, quality must remain at the centre of every step of this journey. The success of the strategy will depend not only on increasing production but also on ensuring that medical products consistently meet the highest standards of quality, safety, and efficacy.”
Conclusion
The $189 million from Gavi is not just money. It is recognition that Africa must produce its own vaccines. It is a response to the lessons of the pandemic. And it is a chance for Kenya to become one of the leaders in African pharmaceuticals.
The country already has the capacity, the strategy, and the political will. All that remains is to seize the moment. Kenya can not only supply its own vaccine needs but also become a supplier for the entire region – creating jobs, attracting investment, and strengthening the nation’s health.
The AVMA+ programme is a once‑in‑a‑generation opportunity. And Kenya is ready to seize it.
Want to stay updated on how Kenya is becoming a regional vaccine manufacturing hub? Download the 888bet app and follow the most important news on the country’s health and development.
Leave a Reply